Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[beta-amyloid cascade: current status and future directions].

T Iwatsubo1

  • 1Department of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo.

Rinsho Shinkeigaku = Clinical Neurology
|July 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2024
Same author

Usability of a Web-Based Registry for Preclinical Alzheimer's Disease: Implications from a Cross-Sectional Online Survey.

The journal of prevention of Alzheimer's disease·2024
Same author

Editorial: Clinical Implementation of Lecanemab: Challenges, Questions and Solutions.

The journal of prevention of Alzheimer's disease·2023
Same author

Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.

The journal of prevention of Alzheimer's disease·2023
Same author

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2022
Same author

Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report.

The journal of prevention of Alzheimer's disease·2022
Same journal

[Utility of acute-phase cerebral blood flow single photon emission computed tomography (SPECT) for evaluating the pathophysiology of Bickerstaff brainstem encephalitis with decorticate posturing].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[Successful treatment with rituximab in unilateral relapsing primary CNS vasculitis: a ‍case report].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[Clinical management of headache comorbid with functional neurological disorder].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[Transient myoclonic state with asterixis related to COVID-19].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[Let's present at a regional meeting].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[Editor's Note].

Rinsho shinkeigaku = Clinical neurology·2026
See all related articles

Amyloid beta 42 peptides are key in Alzheimer's disease (AD) development. Therapies targeting amyloid deposition show promise for AD prevention and cure.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Context:

  • Alzheimer's disease (AD) is characterized by amyloid beta (A beta) peptide deposition.
  • A beta peptides are derived from beta amyloid precursor protein (beta APP).
  • A beta 42 is an early pathological hallmark in AD brains.

Purpose:

  • To investigate the role of A beta 42 in Alzheimer's disease pathogenesis.
  • To explore the genetic links between A beta production and familial AD (FAD).
  • To understand the function of presenilin (PS) 1 and 2 in gamma-secretase activity.

Summary:

  • A beta 42 deposition is an early event in AD.
  • Mutations in beta APP and presenilin genes (PS 1 and 2) are linked to FAD and increased A beta 42 production.

Related Experiment Videos

  • PS 1 and 2 function as catalytic subunits of gamma-secretase, cleaving beta APP and Notch.

    • Impact:

    • Findings support the amyloid cascade hypothesis in AD.
    • Therapeutic strategies targeting beta- and gamma-secretases, and A beta vaccines, offer potential for AD treatment.
    • Further research is needed to validate these therapeutic approaches and the amyloid cascade hypothesis.